DE60334094D1 - Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden - Google Patents
Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werdenInfo
- Publication number
- DE60334094D1 DE60334094D1 DE60334094T DE60334094T DE60334094D1 DE 60334094 D1 DE60334094 D1 DE 60334094D1 DE 60334094 T DE60334094 T DE 60334094T DE 60334094 T DE60334094 T DE 60334094T DE 60334094 D1 DE60334094 D1 DE 60334094D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- helicobacter pylori
- utilines
- pulley
- diseases caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000590002 Helicobacter pylori Species 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 229940037467 helicobacter pylori Drugs 0.000 title abstract 2
- 229930187411 utiline Natural products 0.000 title 1
- ZRZNJUXESFHSIO-UHFFFAOYSA-N Pleuromutilin Natural products CC1C(O)C(C)(C=C)CC(OC(=O)CO)C2(C)C(C)CCC31C2C(=O)CC3 ZRZNJUXESFHSIO-UHFFFAOYSA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- ZRZNJUXESFHSIO-VYTKZBNOSA-N pleuromutilin Chemical compound C([C@H]([C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]2C)OC(=O)CO)C)C[C@]32[C@H]1C(=O)CC3 ZRZNJUXESFHSIO-VYTKZBNOSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0209262.5A GB0209262D0 (en) | 2002-04-23 | 2002-04-23 | Organic compounds |
| PCT/EP2003/004173 WO2003090740A1 (en) | 2002-04-23 | 2003-04-22 | Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60334094D1 true DE60334094D1 (de) | 2010-10-21 |
Family
ID=9935350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60334094T Expired - Lifetime DE60334094D1 (de) | 2002-04-23 | 2003-04-22 | Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7790749B2 (de) |
| EP (1) | EP1501495B1 (de) |
| JP (1) | JP2005529131A (de) |
| AT (1) | ATE480232T1 (de) |
| AU (1) | AU2003239813A1 (de) |
| DE (1) | DE60334094D1 (de) |
| ES (1) | ES2354972T3 (de) |
| GB (1) | GB0209262D0 (de) |
| SI (1) | SI1501495T1 (de) |
| TW (1) | TW200306294A (de) |
| WO (1) | WO2003090740A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0308114D0 (en) * | 2003-04-08 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
| TW200730488A (en) * | 2005-06-27 | 2007-08-16 | Nabriva Therapeutics Forschungs Gmbh | Organic compounds |
| GB0515995D0 (en) * | 2005-08-03 | 2005-09-07 | Sandoz Ag | Organic compounds |
| EP1808431A1 (de) * | 2006-01-16 | 2007-07-18 | Nabriva Therapeutics Forschungs GmbH | Mutilin Derivate und ihre Verwendung als Arzneimittel |
| EP1972618A1 (de) | 2007-03-20 | 2008-09-24 | Nabriva Therapeutics AG | Pleuromutilin-Derivate zur Behandlung von Krankheiten vermittelt durch Mikroben |
| EP2014645A1 (de) * | 2007-07-13 | 2009-01-14 | Nabriva Therapeutics AG | Pleuromutilin-derivate und ihre Verwendung als antimikrobielles Wirkungsmittel |
| EP2159220A1 (de) | 2008-09-02 | 2010-03-03 | Nabriva Therapeutics AG | Organische Verbindungen |
| CN102924350B (zh) * | 2012-10-31 | 2014-04-09 | 中国农业科学院兰州畜牧与兽药研究所 | 截短侧耳素衍生物及其制备方法和应用 |
| CN103265442B (zh) * | 2013-06-05 | 2017-02-08 | 北京理工大学 | 一类新型截短侧耳素衍生物及其制备方法和抗肿瘤用途 |
| CN107810000B (zh) | 2015-06-17 | 2021-03-12 | 纳布里瓦治疗有限责任公司 | 来氟米林的可注射药物组合物 |
| TWI762573B (zh) | 2017-02-10 | 2022-05-01 | 奧地利商納畢瓦治療有限責任公司 | 截短側耳素之純化 |
| CN116687904B (zh) * | 2023-03-28 | 2025-05-06 | 中国药科大学 | 截短侧耳素抗生素在制备抗肿瘤及逆转分子靶向治疗耐药的药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0153277B1 (de) | 1984-02-17 | 1987-08-26 | Sandoz Ag | Neue Pleuromutilinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| CA2042138A1 (en) | 1990-04-18 | 1992-11-09 | Hiroo Abe | Agents for preventing or treating bacterial diseases of fishes |
| AUPO758297A0 (en) * | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
| GB9918037D0 (en) * | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| IL151887A0 (en) * | 2000-04-04 | 2003-04-10 | Smithkline Beecham Plc | 2-hydroxy-mutilin carbamate derivatives for antibacterial use |
| DE10030781A1 (de) * | 2000-06-29 | 2002-01-17 | Hassan Jomaa | Kombinationspräparate von 3-N-Formylhydroxylaminopropylphosphonsäurederivaten oder 3-N-Acetylhydroxylaminopropylphosphonsäurederivaten mit spezielen pharmazeutischen Wirkstoffen |
| GB0017031D0 (en) * | 2000-07-11 | 2000-08-30 | Biochemie Gmbh | Antimicrobials |
| PE20020676A1 (es) * | 2000-09-13 | 2002-08-27 | Biochemie Gmbh | Compuestos de mutilina como antibacterianos |
| GB0024811D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
-
2002
- 2002-04-23 GB GBGB0209262.5A patent/GB0209262D0/en not_active Ceased
-
2003
- 2003-04-21 TW TW092109216A patent/TW200306294A/zh unknown
- 2003-04-22 AT AT03732288T patent/ATE480232T1/de not_active IP Right Cessation
- 2003-04-22 US US10/510,532 patent/US7790749B2/en not_active Expired - Lifetime
- 2003-04-22 SI SI200331922T patent/SI1501495T1/sl unknown
- 2003-04-22 JP JP2003587374A patent/JP2005529131A/ja active Pending
- 2003-04-22 ES ES03732288T patent/ES2354972T3/es not_active Expired - Lifetime
- 2003-04-22 EP EP03732288A patent/EP1501495B1/de not_active Expired - Lifetime
- 2003-04-22 DE DE60334094T patent/DE60334094D1/de not_active Expired - Lifetime
- 2003-04-22 WO PCT/EP2003/004173 patent/WO2003090740A1/en not_active Ceased
- 2003-04-22 AU AU2003239813A patent/AU2003239813A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050131023A1 (en) | 2005-06-16 |
| EP1501495A1 (de) | 2005-02-02 |
| EP1501495B1 (de) | 2010-09-08 |
| SI1501495T1 (sl) | 2011-01-31 |
| JP2005529131A (ja) | 2005-09-29 |
| HK1073250A1 (en) | 2005-09-30 |
| AU2003239813A1 (en) | 2003-11-10 |
| TW200306294A (en) | 2003-11-16 |
| WO2003090740A1 (en) | 2003-11-06 |
| GB0209262D0 (en) | 2002-06-05 |
| ATE480232T1 (de) | 2010-09-15 |
| US7790749B2 (en) | 2010-09-07 |
| ES2354972T3 (es) | 2011-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL374865A1 (en) | Treatment of tnf alpha related disorders | |
| ATE344029T1 (de) | Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern | |
| DE60312309D1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
| ZA200407216B (en) | Tuberculosis treatment. | |
| ATE411399T1 (de) | Behandlung der huntington's krankheit mit epa | |
| EA200401525A1 (ru) | Способы лечения гепатита (варианты ) | |
| DE60334094D1 (de) | Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden | |
| DE60327557D1 (de) | Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie | |
| DE602004022285D1 (de) | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika | |
| DE602004021847D1 (de) | Verfahren zur prävention und behandlung von diabetes mit neurturin | |
| EP1501511A4 (de) | Verfahren zur behandlung von glaukom und anderen erkrankungen, die durch nos-2 expression vermittelt werden, durch hemmung des egfr-wegs | |
| DE60308045D1 (de) | Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes | |
| ATE406171T1 (de) | Aplidine zur behandlung von multiplem myelom | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| SE0301883D0 (sv) | New use II | |
| ATE392212T1 (de) | Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen | |
| ATE453386T1 (de) | Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten | |
| ATE473277T1 (de) | Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten | |
| EA200600989A1 (ru) | Применение габоксадола для лечения бессонницы | |
| DE60331654D1 (de) | Nicht-radioaktives Strontiummittel zur Behandlung von Krebs | |
| SE0301885D0 (sv) | New use IV | |
| DE602006020838D1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum | |
| ATE431157T1 (de) | Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie | |
| NZ516651A (en) | 17-beta-decanoate-4estrene-3-one and 17-beta-cyclohexylpropionate-4-estrene-3-one for treating aggression and stimulating appetite in stags (deer) during puberty especially for promoting and obtaining stag's horn | |
| ATE350034T1 (de) | Verwendung von epothilone zur behandlung hyperparathyreoidismus |